Medistim management invests in company through share purchases

Medistim ASA announced that its management team purchased shares in the company on November 10, 2025, as part of a long-term incentive plan. This initiative was previously approved by the general meeting on May 8, 2025. The shares were acquired at a price of NOK 265.09 per share.

Two new members of management participated in the purchase. Jonas Tyssø, the new chief research and development officer, acquired 3,772 shares, bringing his total holding to 3,722 shares after the transaction. Similarly, Monica Weiseth, the new vp quality assurance and regulatory affairs, purchased 3,772 shares, resulting in a total of 3,772 shares in her possession post-purchase.

In total, Medistim ASA sold 7,545 shares to its management. Following these transactions, the company now holds 54,487 of its own shares.